LOS ANGELES, March 3, 2015 /PRNewswire/ -- ImmunoCellular
Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today
announced that Andrew Gengos, Chief
Executive Officer of ImmunoCellular, will present a corporate
overview and business update at the 27th Annual ROTH
Conference on Tuesday, March 10, 2014
at 8:30 am PT, at the Ritz-Carlton
Hotel, Laguna Niguel,
CA.
To access the live audio webcast of the ROTH presentation,
please log on through a link located in the Investors section of
ImmunoCellular's website at www.imuc.com, under the Events &
Presentations tab. A replay of the webcast will be available one
hour after the conclusion of the live event.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular has concluded a phase II trial of its
lead product candidate, ICT-107, a dendritic cell-based vaccine
targeting multiple tumor-associated antigens for glioblastoma.
ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell
vaccine targeting CD133; ICT-140, a dendritic cell vaccine
targeting ovarian cancer antigens and cancer stem cells; and the
Stem-to-T-cell research program which engineers the patient's
hematopoietic stem cells to generate antigen-specific cancer
killing T-cells. To learn more about ImmunoCellular, please visit
www.imuc.com.
Contact:
For ImmunoCellular Therapeutics, Ltd.
Jane Green.
Investor Relations
415.348.0010
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-to-present-at-roth-conference-on-march-10th-300043145.html
SOURCE ImmunoCellular Therapeutics, Ltd.